These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 31088845)

  • 21. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
    Zhang C; Li J; Wang H; Song SW
    Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
    Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
    Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.
    Patel SH; Bansal AG; Young EB; Batchala PP; Patrie JT; Lopes MB; Jain R; Fadul CE; Schiff D
    AJNR Am J Neuroradiol; 2019 Jul; 40(7):1149-1155. PubMed ID: 31248860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
    Branzoli F; Pontoizeau C; Tchara L; Di Stefano AL; Kamoun A; Deelchand DK; Valabrègue R; Lehéricy S; Sanson M; Ottolenghi C; Marjańska M
    Neuro Oncol; 2019 Jun; 21(6):765-774. PubMed ID: 30726924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deconvolution and network analysis of IDH-mutant lower grade glioma predict recurrence and indicate therapeutic targets.
    Li G; Jiang Y; Lyu X; Cai Y; Zhang M; Wang Z; Li G; Qiao Q
    Epigenomics; 2019 Aug; 11(11):1323-1333. PubMed ID: 31272213
    [No Abstract]   [Full Text] [Related]  

  • 27. CD8
    Kane JR; Zhao J; Tsujiuchi T; Laffleur B; Arrieta VA; Mahajan A; Rao G; Mela A; Dmello C; Chen L; Zhang DY; González-Buendia E; Lee-Chang C; Xiao T; Rothschild G; Basu U; Horbinski C; Lesniak MS; Heimberger AB; Rabadan R; Canoll P; Sonabend AM
    Clin Cancer Res; 2020 Aug; 26(16):4390-4401. PubMed ID: 32430477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.
    Perumal D; Imai N; Laganà A; Finnigan J; Melnekoff D; Leshchenko VV; Solovyov A; Madduri D; Chari A; Cho HJ; Dudley JT; Brody JD; Jagannath S; Greenbaum B; Gnjatic S; Bhardwaj N; Parekh S
    Clin Cancer Res; 2020 Jan; 26(2):450-464. PubMed ID: 31857430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Observation after surgery for low grade glioma: long-term outcome in the light of the 2016 WHO classification.
    Jansen E; Hamisch C; Ruess D; Heiland DH; Goldbrunner R; Ruge MI; Schnell O; Grau SJ
    J Neurooncol; 2019 Dec; 145(3):501-507. PubMed ID: 31621043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
    Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
    Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accelerated progression of IDH mutant glioma after first recurrence.
    Miller JJ; Loebel F; Juratli TA; Tummala SS; Williams EA; Batchelor TT; Arrillaga-Romany I; Cahill DP
    Neuro Oncol; 2019 May; 21(5):669-677. PubMed ID: 30668823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoantigen landscape in metastatic nasopharyngeal carcinoma.
    Lin M; Zhang XL; You R; Yang Q; Zou X; Yu K; Liu YP; Zou RH; Hua YJ; Huang PY; Wang J; Zhao Q; Jiang XB; Tang J; Gu YK; Yu T; He GP; Xie YL; Wang ZQ; Liu T; Chen SY; Zuo ZX; Chen MY
    Theranostics; 2021; 11(13):6427-6444. PubMed ID: 33995666
    [No Abstract]   [Full Text] [Related]  

  • 33. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.
    Compes P; Tabouret E; Etcheverry A; Colin C; Appay R; Cordier N; Mosser J; Chinot O; Delingette H; Girard N; Dufour H; Metellus P; Figarella-Branger D
    J Neurooncol; 2019 May; 142(3):511-520. PubMed ID: 30756272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival.
    Zhang J; Caruso FP; Sa JK; Justesen S; Nam DH; Sims P; Ceccarelli M; Lasorella A; Iavarone A
    Commun Biol; 2019; 2():135. PubMed ID: 31044160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glioma-expressed antigen 2 (GLEA2): a novel protein that can elicit immune responses in glioblastoma patients and some controls.
    Fischer U; Struss AK; Hemmer D; Pallasch CP; Steudel WI; Meese E
    Clin Exp Immunol; 2001 Nov; 126(2):206-13. PubMed ID: 11703362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
    Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
    J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High expression and frequently humoral immune response of melanoma-associated antigen D4 in glioma.
    He SJ; Gu YY; Yu L; Luo B; Fan R; Lin WZ; Lan XW; Lin YD; Zhang QM; Xiao SW; Xie XX
    Int J Clin Exp Pathol; 2014; 7(5):2350-60. PubMed ID: 24966945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GNIFdb: a neoantigen intrinsic feature database for glioma.
    Li W; Sun T; Li M; He Y; Li L; Wang L; Wang H; Li J; Wen H; Liu Y; Chen Y; Fan Y; Xin B; Zhang J
    Database (Oxford); 2022 Feb; 2022():. PubMed ID: 35150127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Models of epigenetic age capture patterns of DNA methylation in glioma associated with molecular subtype, survival, and recurrence.
    Liao P; Ostrom QT; Stetson L; Barnholtz-Sloan JS
    Neuro Oncol; 2018 Jun; 20(7):942-953. PubMed ID: 29432558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.